Physician profile
Gordon Lang
NPI 1790890200
$1,501.16
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $442 · 2021: $77.33.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $481.41 | 2019-2020 | |
| Amgen INC. | $226.63 | 2019-2020 | |
| Pfizer INC. | $172.02 | 2019-2021 | |
| Novo Nordisk INC | $118.19 | 2019-2020 | |
| Mylan Specialty L.P. | $71.61 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $62.12 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $48.07 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.48 | 2019 | |
| Radius Health, INC. | $42.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $41.47 | 2021 | |
| Astellas Pharma US INC | $40.17 | 2019-2020 | |
| Abbvie INC. | $24.42 | 2021 | |
| Allergan, INC. | $22.26 | 2019 | |
| Smith+Nephew, INC. | $20.47 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.14 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.72 | 2020 | |
| Bioventus LLC | $13.67 | 2019 | |
| Eisai INC. | $13.12 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.65 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.